National Institute on Drug Abuse; Notice of Closed Meetings, 54700-54701 [2021-21531]
Download as PDF
<![CDATA[
54700
Federal Register / Vol. 86, No. 189 / Monday, October 4, 2021 / Notices
INSTRUCTIONS FOR THE SF–429 Real
Property Status Report, SF–429 Real
Property Status Report (Cover Page),
SF–429–A Real Property Status Report
ATTACHMENT A (General Reporting),
SF–429–B Real Property Status Report
ATTACHMENT B (Request to Acquire,
Improve or Furnish), and SF–429–C
Real Property Status Report
ATTACHMENT C (Disposition or
Encumbrance Request) forms allow the
applicants to provide real property
details as part of their grant proposals.
These forms are evaluated by Federal
agencies as part of the overall grant
application. This IC expires on February
28, 2022. Grants.gov seeks a three-year
clearance of these collections.
Type of Respondent: The
INSTRUCTIONS FOR THE SF–429 Real
Property Status Report, SF–429 Real
Property Status Report (Cover Page),
SF–429–A Real Property Status Report
ATTACHMENT A (General Reporting),
SF–429–B Real Property Status Report
ATTACHMENT B (Request to Acquire,
Improve or Furnish), and SF–429–C
Real Property Status Report
ATTACHMENT C (Disposition or
Encumbrance Request) forms are used
by organizations to apply for Federal
financial assistance in the form of
grants. These forms are submitted to the
Federal grant-making agencies for
evaluation and review.
ANNUALIZED BURDEN HOUR TABLE
Forms
(if necessary)
Respondents
(if necessary)
INSTRUCTIONS FOR THE SF–429 Real
Property Status Report.
SF–429 Real Property Status Report (Cover
Page), SF–429–A Real Property Status
Report.
ATTACHMENT A (General Reporting), SF–
429–B Real Property Status Report.
ATTACHMENT B (Request to Acquire, Improve or Furnish), and SF–429–C Real
Property.
Status Report ATTACHMENT C (Disposition or Encumbrance Request).
Total .......................................................
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
[FR Doc. 2021–21558 Filed 10–1–21; 8:45 am]
BILLING CODE 4151–AE–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Number of
respondents
22:52 Oct 01, 2021
Jkt 256001
Average
burden per
response
Total burden
hours
Grant-seeking organizations
100,000
1
0.5
50,000
Grant-seeking organizations
100,000
1
1
100,000
Grant-seeking organizations
100,000
1
1
100,000
Grant-seeking organizations
100,000
1
100,000
........................
Grant-seeking organizations
100,000
1
1
........................
........................
1
........................
450,000
...............................................
Early Life (IDEaL) (U01, U19 Clinical Trial
Not Allowed).
Date: October 26–27, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Margaret A. Morris Fears,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20852, (301) 761–5444,
maggie.morrisfears@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 28, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–21530 Filed 10–1–21; 8:45 am]
BILLING CODE 4140–01–P
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Immune Development in
VerDate Sep<11>2014
Number of
responses per
respondents
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Initial Review Group;
Medication Development Research Study
Section.
Date: November 3, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
E:\FR\FM\04OCN1.SGM
04OCN1
Federal Register / Vol. 86, No. 189 / Monday, October 4, 2021 / Notices
Contact Person: Preethy Nayar, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, 3WFN, MSC 6021,
Bethesda, MD 20892, 301–443–4577,
nayarp2@csr.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Developing Digital Therapeutics for
Substance Use Disorders (UG3/UH3 Clinical
Trial optional).
Date: November 5, 2021.
Time: 5:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Jenny Raye Browning,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,
301 North Stonestreet Avenue, 3WFN, MSC
6021, Bethesda, MD 20892, (301) 443–4577,
jenny.browning@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Mobile
Health Solutions to Rectify Digital Inequality
in Communities Affected by Drug Addiction
(R43/R44 Clinical Trial Optional).
Date: November 12, 2021.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Trinh T. Tran, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5843, trinh.tran@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 28, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–21531 Filed 10–1–21; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: October 27, 2021.
Time: 10:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G45,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Vanitha S. Raman, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G45, Rockville, MD
20852, 301–761–7949, vanitha.raman@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 28, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–21534 Filed 10–1–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4140–01–P
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
22:52 Oct 01, 2021
Jkt 256001
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
54701
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Arthritis and
Musculoskeletal and Skin Diseases Initial
Review Group; Arthritis and Musculoskeletal
and Skin Diseases Clinical Trials Study
Section.
Date: October 14–15, 2021.
Time: 9:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Arthritis and
Musculoskeletal and Skin Diseases, 6701
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Yin Liu, Ph.D., M.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute of Arthritis, and
Musculoskeletal and Skin Diseases. National
Institute of Health, Bethesda, MD 20892,
301–496–0505, liuy@mail.nih.gov
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
Diseases Special Emphasis Panel; NIAMS
Member Conflict Meeting.
Date: October 19, 2021.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Arthritis and
Musculoskeletal and Skin Diseases, 6701
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Yasuko Furumoto, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute of Arthritis,
Musculoskeletal and Skin Diseases, 6701
Democracy Boulevard, Suite 820, Bethesda,
MD 20892, 301–827–7835,
yasuko.furumoto@nih.gov.
Name of Committee: Arthritis and
Musculoskeletal and Skin Diseases Initial
Review Group; Arthritis and Musculoskeletal
and Skin Diseases Special Grants Study
Section.
Date: October 21–22, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Arthritis and
Musculoskeletal and Skin Diseases, 6701
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Helen Lin, Ph.D.,
Scientific Review Officer, NIH/NIAMS/RB,
6701 Democracy Blvd., Suite 800, Plaza One,
Bethesda, MD 20817, 301–594–4952, linh1@
mail.nih.gov.
Name of Committee: National Institute of
Arthritis and Musculoskeletal and Skin
E:\FR\FM\04OCN1.SGM
04OCN1
]]>Agencies
[Federal Register Volume 86, Number 189 (Monday, October 4, 2021)]
[Notices]
[Pages 54700-54701]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-21531]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Initial
Review Group; Medication Development Research Study Section.
Date: November 3, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
[[Page 54701]]
Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Research, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 3WFN,
MSC 6021, Bethesda, MD 20892, 301-443-4577, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Developing Digital Therapeutics for Substance Use
Disorders (UG3/UH3 Clinical Trial optional).
Date: November 5, 2021.
Time: 5:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Jenny Raye Browning, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, 301 North Stonestreet Avenue,
3WFN, MSC 6021, Bethesda, MD 20892, (301) 443-4577,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mobile Health Solutions to Rectify Digital
Inequality in Communities Affected by Drug Addiction (R43/R44
Clinical Trial Optional).
Date: November 12, 2021.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer,
Office of Extramural Policy and Review, Division of Extramural
Research, National Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5843,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 28, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-21531 Filed 10-1-21; 8:45 am]
BILLING CODE 4140-01-P
